TABLE 3.
Cross-resistance comparison of ceftazidime-avibactam, ceftazidime, meropenem, piperacillin-tazobactam, gentamicin, amikacin, and levofloxacin against P. aeruginosa isolates tested in this studya
| Resistance group | No. of isolates (%) susceptible to drug(s): |
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAZ-AVI | CAZ | MEM | PT | GEN | AMK | LEV | CAZ + MEM | CAZ + PT | CAZ + GEN | CAZ + AMK | CAZ + LEV | MEM + PT | MEM + GEN | MEM + AMK | MEM + LEV | PT + GEN | PT + AMK | PT + LEV | GEN + AMK | GEN + LEV | AMK + LEV | CAZ-AVI + AMK | |
| All (n = 7,452) | 7,228 (97.0) | 6,284 (84.3) | 6,096 (82.0) | 5,996 (80.5) | 6,578 (88.3) | 7,228 (97.0) | 5,583 (74.9) | 6,800 (91.3) | 6,379 (85.6) | 7,090 (95.1) | 7,334 (98.4) | 6,758 (90.7) | 6,658 (89.3) | 6,981 (93.7) | 7,328 (98.3) | 6,521 (87.5) | 7,023 (94.2) | 7,331 (98.4) | 6,590 (88.4) | 7,230 (97.0) | 6,841 (91.8) | 7,310 (98.1) | 7,405 (99.4) |
| CAZ-NS (≥16 mg/liter; n = 1,168) | 946 (81.0) | 0 (0.0) | 516 (44.3) | 95 (8.1) | 806 (69.1) | 1,050 (89.9) | 474 (40.6) | 516 (44.2) | 95 (8.1) | 806 (69.0) | 1,050 (89.9) | 474 (40.6) | 559 (47.9) | 875 (74.9) | 1,078 (92.3) | 651 (55.7) | 841 (72.0) | 1,068 (91.4) | 520 (44.5) | 1,051 (90.0) | 855 (73.2) | 1,075 (92.0) | 1,123 (96.2) |
| MEM-NS (≥4 mg/liter; n = 1,341) | 1,156 (86.2) | 691 (51.5) | 0 (0.0) | 550 (41.0) | 870 (64.9) | 1,217 (90.8) | 411 (30.6) | 691 (51.5) | 734 (54.7) | 1,048 (78.2) | 1,251 (93.3) | 824 (61.4) | 550 (41.0) | 870 (64.9) | 1,217 (90.8) | 411 (30.6) | 1,001 (74.6) | 1,241 (92.5) | 724 (54.0) | 1,218 (90.8) | 924 (68.9) | 1,239 (92.4) | 1,298 (96.8) |
| PT-NS (≥32 mg/liter; n = 1,449) | 1,238 (85.4) | 376 (25.9) | 655 (45.3) | 0 (0.0) | 1,020 (70.4) | 1,328 (91.6) | 588 (40.6) | 840 (58.0) | 376 (25.9) | 1,122 (77.4) | 1,349 (93.1) | 801 (55.3) | 655 (45.2) | 1,109 (76.5) | 1,349 (93.1) | 832 (57.4) | 1,020 (70.4) | 1,328 (91.6) | 588 (40.6) | 1,328 (91.6) | 1,072 (74.0) | 1,347 (93.0) | 1,407 (97.1) |
| NS to CAZ, MER, and PT (n = 607) | 432 (71.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 336 (55.4) | 522 (86.0) | 121 (19.9) | 0 (0.0) | 0 (0.0) | 336 (55.4) | 522 (86.0) | 121 (19.9) | 0 (0.0) | 336 (55.4) | 522 (86.0) | 121 (19.9) | 336 (55.4) | 522 (86.0) | 121 (19.9) | 522 (86.0) | 358 (59.0) | 531 (87.5) | 567 (93.4) |
| LEV-NS (≥4 mg/liter; n = 1,868) | 1,688 (90.4) | 1,174 (62.8) | 937 (50.2) | 1,006 (53.9) | 1,257 (67.3) | 1,726 (92.4) | 0 (0.0) | 1,351 (72.3) | 1,220 (65.3) | 1,555 (83.2) | 1,775 (95.0) | 1,174 (62.8) | 1,251 (67.0) | 1,451 (77.7) | 1,766 (94.5) | 937 (50.2) | 1,491 (79.8) | 1,766 (94.5) | 1,006 (53.9) | 1,727 (92.5) | 1,257 (67.3) | 1,726 (92.4) | 1,827 (97.8) |
| GEN-NS (≥8 mg/liter; n = 873) | 765 (87.6) | 512 (58.6) | 402 (46.0) | 445 (51.0) | 0 (0.0) | 651 (74.6) | 262 (30.0) | 580 (66.4) | 547 (62.7) | 512 (58.6) | 756 (86.6) | 560 (64.1) | 533 (61.1) | 402 (46.0) | 750 (85.9) | 456 (52.2) | 445 (51.0) | 752 (86.1) | 496 (56.8) | 651 (74.6) | 262 (30.0) | 732 (83.8) | 828 (94.8) |
| AMK-NS (≥32 mg/liter; n = 224) | 178 (79.5) | 106 (47.3) | 100 (44.6) | 103 (46.0) | 2 (0.9) | 0 (0.0) | 82 (36.6) | 134 (59.8) | 124 (55.4) | 107 (47.8) | 106 (47.3) | 131 (58.5) | 124 (55.4) | 101 (45.1) | 100 (44.6) | 122 (54.5) | 103 (46.0) | 103 (46.0) | 122 (54.5) | 2 (0.9) | 83 (37.1) | 82 (36.6) | 178 (79.5) |
| COL-NS (≥4 mg/liter; n = 45) | 40 (88.9) | 39 (86.7) | 35 (77.8) | 36 (80.0) | 40 (88.9) | 43 (95.6) | 35 (77.8) | 40 (88.9) | 39 (86.7) | 43 (95.6) | 43 (95.6) | 41 (91.1) | 39 (86.7) | 42 (93.3) | 43 (95.6) | 39 (86.7) | 43 (95.6) | 43 (95.6) | 41 (91.1) | 43 (95.6) | 41 (91.1) | 43 (95.6) | 43 (95.6) |
| CAZ-AVI-NS (n = 224) | 0 (0.0) | 2 (0.9) | 39 (17.4) | 13 (5.8) | 116 (51.8) | 178 (79.5) | 44 (19.6) | 39 (17.4) | 15 (6.7) | 116 (51.8) | 178 (79.5) | 46 (20.5) | 49 (21.9) | 122 (54.5) | 181 (80.8) | 63 (28.1) | 125 (55.8) | 183 (81.7) | 54 (24.1) | 179 (79.9) | 125 (55.8) | 183 (81.7) | 178 (79.5) |
| MDR (n = 1,151) | 945 (82.1) | 318 (27.6) | 246 (21.4) | 178 (15.5) | 588 (51.1) | 1,002 (87.1) | 170 (14.8) | 510 (44.3) | 362 (31.5) | 794 (69.0) | 1,037 (90.1) | 465 (40.4) | 397 (34.5) | 697 (60.6) | 1,035 (89.9) | 392 (34.1) | 728 (63.2) | 1,032 (89.7) | 336 (29.2) | 1,004 (87.2) | 645 (56.0) | 1,026 (89.1) | 1,105 (96.0) |
| XDR (n = 698) | 529 (75.8) | 132 (18.9) | 53 (7.6) | 40 (5.7) | 266 (38.1) | 581 (83.2) | 29 (4.2) | 170 (24.4) | 151 (21.6) | 370 (53.0) | 602 (86.2) | 155 (22.2) | 93 (13.3) | 319 (45.7) | 590 (84.5) | 82 (11.7) | 306 (43.8) | 589 (84.4) | 68 (9.7) | 581 (83.2) | 294 (42.1) | 591 (84.7) | 654 (93.7) |
a
Abbreviations: CAZ, ceftazidime; NS, nonsusceptible; MEM, meropenem; PT, piperacillin-tazobactam; LEV, levofloxacin; GEN, gentamicin; AMK, amikacin; COL, colistin; CAZ-AVI, ceftazidime-avibactam; MDR, multidrug resistant; XDR, extensively drug resistant.